Login / Signup

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity.

Ivan Marquez-RodasMaría Angela AznarAntonio CallesIgnacio Melero
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.
Keyphrases
  • toll like receptor
  • immune response
  • nuclear factor
  • inflammatory response
  • single cell
  • cell therapy
  • combination therapy